These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 38230716)
1. Investigating the Factor Structure of the Preclinical Alzheimer Cognitive Composite and Cognitive Function Index across Racial/Ethnic, Sex, and Aβ Status Groups in the A4 Study. Ruthirakuhan M; Wood Alexander M; Cogo-Moreira H; Robinson T; Amariglio R; Buckley RF; Sperling RA; Swardfager W; Black SE; Rabin JS J Prev Alzheimers Dis; 2024; 11(1):48-55. PubMed ID: 38230716 [TBL] [Abstract][Full Text] [Related]
2. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998 [TBL] [Abstract][Full Text] [Related]
3. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS; JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387 [TBL] [Abstract][Full Text] [Related]
4. Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4. Molina-Henry D; Langford O; Donohue MC; Raman R; Aisen P; Johnson KA; Rissman RA; Sperling R J Prev Alzheimers Dis; 2024; 11(4):831-837. PubMed ID: 39044491 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal Trajectories of the Cognitive Function Index in the A4 Study. Amariglio RE; Grill JD; Rentz DM; Marshall GA; Donohue MC; Liu A; Aisen PS; Sperling RA J Prev Alzheimers Dis; 2024; 11(4):838-845. PubMed ID: 39044492 [TBL] [Abstract][Full Text] [Related]
6. Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study. Papp KV; Maruff P; Rentz DM; Donohue MC; Liu A; Aisen PS; Sperling RA J Prev Alzheimers Dis; 2024; 11(4):846-856. PubMed ID: 39044493 [TBL] [Abstract][Full Text] [Related]
9. Measurement invariance of neuropsychological measures of cognitive aging across race/ethnicity by sex/gender groups. Avila JF; Rentería MA; Witkiewitz K; Verney SP; Vonk JMJ; Manly JJ Neuropsychology; 2020 Jan; 34(1):3-14. PubMed ID: 31464473 [TBL] [Abstract][Full Text] [Related]
10. Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease. Insel PS; Kumar A; Hansson O; Mattsson-Carlgren N; Neurology; 2023 Jul; 101(1):e20-e29. PubMed ID: 37085326 [TBL] [Abstract][Full Text] [Related]
11. A Data-Driven Cognitive Composite Sensitive to Amyloid-β for Preclinical Alzheimer's Disease. Liu S; Maruff P; Fedyashov V; Masters CL; Goudey B J Alzheimers Dis; 2024; 101(3):889-899. PubMed ID: 39269831 [TBL] [Abstract][Full Text] [Related]
12. Association of Alcohol Consumption with Cognition in Older Population: The A4 Study. Nallapu BT; Petersen KK; Lipton RB; Grober E; Sperling RA; Ezzati A J Alzheimers Dis; 2023; 93(4):1381-1393. PubMed ID: 37182868 [TBL] [Abstract][Full Text] [Related]
13. Sex Differences in the Associations of Obesity with Tau, Amyloid PET, and Cognitive Outcomes in Preclinical Alzheimer's Disease: Cross-Sectional A4 Study. Wang X; Sundermann EE; Buckley RF; Reas ET; McEvoy LK; Banks SJ; J Alzheimers Dis; 2023; 95(2):615-624. PubMed ID: 37574737 [TBL] [Abstract][Full Text] [Related]
14. The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial. Papp KV; Rentz DM; Maruff P; Sun CK; Raman R; Donohue MC; Schembri A; Stark C; Yassa MA; Wessels AM; Yaari R; Holdridge KC; Aisen PS; Sperling RA J Prev Alzheimers Dis; 2021; 8(1):59-67. PubMed ID: 33336226 [TBL] [Abstract][Full Text] [Related]
15. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. Raman R; Quiroz YT; Langford O; Choi J; Ritchie M; Baumgartner M; Rentz D; Aggarwal NT; Aisen P; Sperling R; Grill JD JAMA Netw Open; 2021 Jul; 4(7):e2114364. PubMed ID: 34228129 [TBL] [Abstract][Full Text] [Related]
16. Subjective cognitive decline across ethnoracial groups in the A4 study. Robinson T; Klinger H; Buckley R; Deters KD; Quiroz YT; Rentz D; Rabin JS; Sperling RA; Amariglio RE Alzheimers Dement; 2023 Sep; 19(9):4084-4093. PubMed ID: 37218387 [TBL] [Abstract][Full Text] [Related]
17. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment. Insel PS; Hansson O; Mattsson-Carlgren N JAMA Neurol; 2021 Feb; 78(2):229-235. PubMed ID: 33044487 [TBL] [Abstract][Full Text] [Related]
18. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Mormino EC; Papp KV; Rentz DM; Donohue MC; Amariglio R; Quiroz YT; Chhatwal J; Marshall GA; Donovan N; Jackson J; Gatchel JR; Hanseeuw BJ; Schultz AP; Aisen PS; Johnson KA; Sperling RA Alzheimers Dement; 2017 Sep; 13(9):1004-1012. PubMed ID: 28253478 [TBL] [Abstract][Full Text] [Related]
19. Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging. Winer JR; Deters KD; Kennedy G; Jin M; Goldstein-Piekarski A; Poston KL; Mormino EC JAMA Neurol; 2021 Oct; 78(10):1187-1196. PubMed ID: 34459862 [TBL] [Abstract][Full Text] [Related]
20. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial. Molina-Henry DP; Raman R; Liu A; Langford O; Johnson K; Shum LK; Glover CM; Dhadda S; Irizarry M; Jimenez-Maggiora G; Braunstein JB; Yarasheski K; Venkatesh V; West T; Verghese PB; Rissman RA; Aisen P; Grill JD; Sperling RA Alzheimers Dement; 2024 Jun; 20(6):3827-3838. PubMed ID: 38629508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]